Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.93
Percentage change 2.92	%

Peers: PFE VRTX MRK NVO SNY LLY TAK VTRS XENE NBIX

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	8.48%	Shs Outstand	63.49M	Perf Week	11.05%
Market Cap	4.33B	Forward P/E	-	EPS next Y	-1.38	Insider Trans	-5.30%	Shs Float	58.22M	Perf Month	5.38%
Income	-173.99M	PEG	-	EPS next Q	-0.64	Inst Own	95.60%	Short Float	8.71%	Perf Quarter	34.10%
Sales	136.86M	P/S	31.66	EPS this Y	37.85%	Inst Trans	-0.01%	Short Ratio	7.11	Perf Half Y	13.37%
Book/sh	0.30	P/B	228.25	EPS next Y	48.72%	ROA	-52.28%	Short Interest	5.07M	Perf Year	76.54%
Cash/sh	4.94	P/C	13.78	EPS next 5Y	-	ROE	-418.97%	52W Range	38.85 - 68.58	Perf YTD	21.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.34%	ROI	-63.30%	52W High	-0.69%	Beta	2.30
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	-	Gross Margin	89.12%	52W Low	75.30%	ATR (14)	2.68
Dividend Ex-Date	-	Current Ratio	3.30	EPS Y/Y TTM	39.30%	Oper. Margin	-126.13%	RSI (14)	64.14	Volatility	2.44% 3.13%
Employees	283	Debt/Eq	13.60	Sales Y/Y TTM	48.88%	Profit Margin	-127.12%	Recom	1.00	Target Price	83.42
Option/Short	Yes / Yes	LT Debt/Eq	13.50	EPS Q/Q	65.72%	Payout	-	Rel Volume	0.99	Prev Close	66.18
Sales Surprise	-18.57%	EPS Surprise	-16.68%	Sales Q/Q	25.94%	Earnings	May 07 BMO	Avg Volume	712.98K	Price	68.11
SMA20	10.53%	SMA50	13.16%	SMA200	22.26%	Trades		Volume	707,933	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy	$63
Mar-05-25	Resumed	Stifel	Buy	$78
Jan-02-25	Initiated	Jefferies	Buy	$80
Dec-20-24	Initiated	Oppenheimer	Outperform	$76
Oct-21-24	Initiated	Guggenheim	Buy	$70
Sep-18-24	Initiated	H.C. Wainwright	Buy	$64
Sep-17-24	Initiated	JMP Securities	Mkt Outperform	$64
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15
Sep-14-21	Resumed	Goldman	Neutral	$14
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral

Show Previous Ratings

Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-05-25 08:06AM	This IBD 50 Biotech's Got 'Rhythm' - And Flashes 3 Telltale Clues (Investor's Business Daily)
May-29-25 12:50PM	Funds Go All In On Weight-Loss Leader; Stock Nears Highs (Investor's Business Daily)
May-14-25 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program (GlobeNewswire)
May-08-25 03:10AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... (GuruFocus.com) -6.05%
03:22PM	Loading…
May-07-25 03:22PM	Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment (Seeking Alpha)
03:21PM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-06-25 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-23-25 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (GlobeNewswire)
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +5.04%
01:38PM	Loading…
01:38PM	Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (Seeking Alpha)
12:10PM	5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008 (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks)
Apr-07-25 04:09PM	This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5% (GuruFocus.com) +17.06%
12:30PM	Rhythm seeks market expansion for Imcivree following Phase III victory (Clinical Trials Arena)
12:23PM	Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder (Benzinga)
07:51AM	Obesity drug data helps Rhythm defy market slide (BioPharma Dive)
07:00AM	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-06-25 12:00PM	Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Mar-20-25 04:55PM	Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
04:01PM	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. (GlobeNewswire)
Mar-19-25 04:23PM	Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan (SeekingAlpha) +5.58%
04:01PM	Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan (GlobeNewswire)
Mar-18-25 07:00AM	Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration (GlobeNewswire)
02:07AM	Loading…
Feb-27-25 02:07AM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38AM	Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-13-25 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February (GlobeNewswire)
Jan-28-25 09:55AM	Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet (Zacks)
Jan-22-25 08:50AM	Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-10-25 07:15AM	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones (GlobeNewswire)
Jan-02-25 10:15AM	Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential (TipRanks) +7.31%
Dec-20-24 02:24PM	Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential (Benzinga)
02:15PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old (GlobeNewswire)
Dec-06-24 06:48AM	Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities (TipRanks)
Dec-03-24 06:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old (GlobeNewswire)
Nov-18-24 12:02PM	Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone (Investor's Business Daily)
07:00AM	Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide (GlobeNewswire)
Nov-13-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology (GlobeNewswire) -6.23%
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 02:29AM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +11.38%
Nov-05-24 05:10PM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.15%
04:01PM	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 04:01PM	Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 (GlobeNewswire) +8.12%
Oct-29-24 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 06:00AM	Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome (GlobeNewswire)
Oct-23-24 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 (GlobeNewswire)
Oct-08-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-21-24 02:23AM	Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish (Insider Monkey)
Sep-18-24 10:46AM	Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Sep-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +7.37%
Sep-10-24 01:55PM	Biotech Stock Near Buy Point Amid Impressive Sales Track Record (Investor's Business Daily)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
Aug-26-24 08:02AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old (GlobeNewswire) +8.41%
08:00AM	Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September (GlobeNewswire)
Aug-13-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-06-24 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 09:10AM	Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old (GlobeNewswire)
Jul-23-24 08:00AM	Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity (GlobeNewswire)
07:30AM	Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.00% +7.34%
Jul-08-24 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-28-24 08:00AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
Jun-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.36%
Jun-03-24 04:02PM	Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 (GlobeNewswire) +6.08%
08:02AM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference (GlobeNewswire)
May-22-24 04:00AM	Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome (GlobeNewswire)
May-09-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
May-08-24 10:51AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:06AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ... (GuruFocus.com)
May-07-24 10:34PM	Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -10.32%
02:52PM	The 3 Best Nasdaq Stocks to Buy in May 2024 (InvestorPlace)
08:58AM	Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell (MT Newswires)
08:36AM	Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges (GuruFocus.com)
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting (GlobeNewswire)
Apr-30-24 10:01AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline (Zacks)
Apr-29-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology (GlobeNewswire)
Apr-28-24 09:20AM	Jim Cramer Portfolio: 11 Latest Stocks to Buy (Insider Monkey)
Apr-24-24 04:01PM	Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (GlobeNewswire)
Apr-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-24 08:00AM	Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing (GlobeNewswire)
Mar-25-24 08:00AM	Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist (GlobeNewswire)
Mar-22-24 07:01PM	Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-20-24 01:49AM	Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares (GuruFocus.com)
01:49AM	Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ... (GuruFocus.com)
01:49AM	Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAMELA CRAMER	Officer	Jun 06 '25	Proposed Sale	66.18	7,031	465,312		Jun 06 04:25 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Option Exercise	4.59	65,431	300,328	68,431	Jun 05 04:16 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	65.22	65,431	4,267,494	3,000	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Option Exercise	4.59	43,620	200,216	245,445	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Sale	65.05	43,620	2,837,333	201,825	Jun 05 04:16 PM
DAVID W MCGIRR	Director	Jun 03 '25	Proposed Sale	63.66	65,431	4,165,337		Jun 03 04:27 PM
DAVID MEEKER	Director	Jun 03 '25	Proposed Sale	63.66	43,621	2,776,913		Jun 03 04:27 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Option Exercise	6.88	23,400	160,992	133,329	Jun 03 04:15 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Sale	61.41	23,400	1,437,010	109,929	Jun 03 04:15 PM
HUNTER SMITH	Officer	May 30 '25	Proposed Sale	61.88	23,400	1,447,992		May 30 04:35 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Option Exercise	6.80	7,031	47,811	26,240	May 01 04:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Sale	65.09	7,031	457,663	19,209	May 01 04:53 PM
Mazabraud Yann	EVP, Head of International	Apr 29 '25	Sale	65.08	6,745	438,946	37,655	May 01 04:52 PM
YANN MAZZABRAUD	Officer	Apr 29 '25	Proposed Sale	64.41	6,745	434,445		Apr 29 04:21 PM
PAMELA CRAMER	Officer	Apr 29 '25	Proposed Sale	64.41	7,031	452,867		Apr 29 04:20 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Option Exercise	13.43	20,760	278,853	39,969	Apr 10 05:17 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Sale	60.14	20,760	1,248,490	19,209	Apr 10 05:17 PM
Mazabraud Yann	EVP, Head of International	Apr 08 '25	Sale	60.99	17,750	1,082,497	22,620	Apr 10 05:16 PM
PAMELA CRAMER	Officer	Apr 08 '25	Proposed Sale	54.96	20,760	1,140,970		Apr 08 04:18 PM
YANN MAZZABRAUD	Officer	Apr 08 '25	Proposed Sale	54.96	17,750	975,540		Apr 08 04:16 PM
German Christopher Paul	Corporate Controller & CAO	Mar 21 '25	Sale	54.23	344	18,655	2,889	Mar 24 05:47 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Option Exercise	22.28	75,000	1,671,000	115,370	Mar 18 09:16 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Sale	51.48	75,000	3,861,272	40,370	Mar 18 09:16 PM
YANN MAZZABRAUD	Officer	Mar 14 '25	Proposed Sale	50.24	75,000	3,768,000		Mar 14 04:21 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '25	Sale	57.22	2,215	126,742	109,929	Feb 19 09:50 PM
Shulman Joseph	Chief Technical Officer	Feb 19 '25	Sale	57.22	1,228	70,266	8,509	Feb 19 09:49 PM
Meeker David P	President and CEO	Feb 19 '25	Sale	57.22	9,896	566,249	201,281	Feb 19 09:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 19 '25	Sale	57.22	2,035	116,443	5,858	Feb 19 09:46 PM
German Christopher Paul	Corporate Controller & CAO	Feb 19 '25	Sale	57.22	635	36,335	2,070	Feb 19 09:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 19 '25	Sale	57.22	982	56,190	19,209	Feb 19 09:43 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '25	Sale	56.39	751	42,347	105,544	Feb 14 04:59 PM
Shulman Joseph	Chief Technical Officer	Feb 12 '25	Sale	56.40	469	26,452	5,612	Feb 14 04:57 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 12 '25	Sale	56.39	1,815	102,348	3,598	Feb 14 04:55 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '25	Sale	58.00	1,205	69,890	2,393	Feb 14 04:55 PM
JENNIFER KAYDEN LEE	Officer	Feb 13 '25	Proposed Sale	57.64	1,205	69,456		Feb 13 04:31 PM
JENNIFER KAYDEN LEE	Officer	Feb 12 '25	Proposed Sale	57.58	1,205	69,384		Feb 12 04:42 PM
Shulman Joseph	Chief Technical Officer	Feb 11 '25	Sale	57.51	794	45,663	6	Feb 11 09:47 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 09 '25	Option Exercise	6.80	4,189	28,485	8,598	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 10 '25	Sale	58.91	4,189	246,783	4,409	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 11 '25	Sale	57.51	1,027	59,063	5,413	Feb 11 09:46 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 11 '25	Sale	57.51	701	40,315	16,891	Feb 11 09:45 PM
Smith Hunter C	Chief Financial Officer	Feb 11 '25	Sale	57.51	1,296	74,533	106,295	Feb 11 09:44 PM
JENNIFER KAYDEN LEE	Officer	Feb 10 '25	Proposed Sale	59.18	4,189	247,905		Feb 10 04:34 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 05 '25	Sale	60.55	3,066	185,640	972	Feb 07 05:05 PM
JENNIFER KAYDEN LEE	Officer	Feb 05 '25	Proposed Sale	59.95	3,066	183,807		Feb 05 04:20 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '25	Sale	59.43	1,678	99,724	101,186	Feb 04 09:27 PM
Shulman Joseph	Chief Technical Officer	Feb 04 '25	Sale	59.43	1,281	76,130	2,657	Feb 04 09:26 PM
Meeker David P	President and CEO	Feb 04 '25	Sale	59.43	4,278	254,242	189,927	Feb 04 09:25 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 04 '25	Sale	59.43	1,447	85,995	4,038	Feb 04 09:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 04 '25	Sale	59.43	902	53,606	15,248	Feb 04 09:22 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Option Exercise	19.59	60,981	1,194,709	67,833	Nov 13 09:04 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Sale	66.33	66,861	4,434,882	972	Nov 13 09:04 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Option Exercise	12.63	13,281	167,760	13,281	Nov 13 09:02 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Sale	66.44	13,281	882,341	0	Nov 13 09:02 PM
JENNIFER KAYDEN LEE	Officer	Nov 11 '24	Proposed Sale	67.33	66,861	4,501,751		Nov 12 07:55 AM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Option Exercise	19.02	4,688	89,166	18,188	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Option Exercise	19.02	4,687	89,147	18,187	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Sale	65.00	4,688	304,720	13,500	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Sale	60.00	4,687	281,220	13,500	Nov 08 04:15 PM
PAMELA CRAMER	Officer	Nov 07 '24	Proposed Sale	62.65	4,688	293,703		Nov 07 04:36 PM
PAMELA CRAMER	Officer	Nov 06 '24	Proposed Sale	56.25	4,687	263,644		Nov 06 05:07 PM
GOOD JENNIFER L	Director	Sep 17 '24	Option Exercise	21.54	31,751	684,066	34,751	Sep 19 04:30 PM
GOOD JENNIFER L	Director	Sep 17 '24	Sale	52.40	31,751	1,663,803	3,000	Sep 19 04:30 PM
JENNIFER GOOD	Director	Sep 17 '24	Proposed Sale	49.52	31,751	1,572,310		Sep 17 04:42 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Option Exercise	19.02	4,099	77,963	17,599	Sep 11 04:32 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Sale	50.03	4,099	205,062	13,500	Sep 11 04:32 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Option Exercise	10.51	17,501	183,944	20,501	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Option Exercise	18.99	3,199	60,749	6,199	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Sale	49.65	17,501	868,923	3,000	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Sale	50.04	3,199	160,068	3,000	Sep 11 04:31 PM
GOOD JENNIFER L	Director	Sep 09 '24	Option Exercise	13.34	37,241	496,706	40,241	Sep 11 04:30 PM
GOOD JENNIFER L	Director	Sep 09 '24	Sale	50.45	37,241	1,878,700	3,000	Sep 11 04:30 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Sep 10 '24	Proposed Sale	50.66	17,501	886,601		Sep 10 04:22 PM
JENNIFER GOOD	Director	Sep 09 '24	Proposed Sale	49.25	16,749	824,888		Sep 09 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Option Exercise	19.02	3,200	60,864	16,700	Aug 28 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Sale	50.01	3,200	160,018	13,500	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Option Exercise	18.99	4,300	81,657	7,300	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Sale	50.01	4,300	215,029	3,000	Aug 28 04:31 PM
GOOD JENNIFER L	Director	Aug 26 '24	Option Exercise	18.63	14,508	270,322	17,508	Aug 28 04:30 PM
GOOD JENNIFER L	Director	Aug 26 '24	Sale	50.01	14,508	725,526	3,000	Aug 28 04:30 PM
JENNIFER GOOD	Director	Aug 26 '24	Proposed Sale	46.12	35,000	1,614,200		Aug 26 04:27 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 26 '24	Proposed Sale	46.12	7,499	345,854		Aug 26 04:27 PM
PAMELA CRAMER	Officer	Aug 26 '24	Proposed Sale	46.12	7,299	336,630		Aug 26 04:26 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Option Exercise	4.15	10,000	41,500	13,000	Aug 14 04:15 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Sale	44.65	10,000	446,462	3,000	Aug 14 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Option Exercise	19.02	30,771	585,264	62,506	Aug 13 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Sale	45.15	49,006	2,212,498	13,500	Aug 13 04:45 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 12 '24	Proposed Sale	45.26	10,000	452,600		Aug 12 04:13 PM
PAMELA CRAMER	Officer	Aug 09 '24	Proposed Sale	45.87	49,006	2,247,905		Aug 09 04:09 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '24	Sale	49.06	1,395	68,439	31,735	Jul 30 05:09 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Option Exercise	27.35	10,468	286,300	10,498	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Sale	53.00	10,468	554,817	30	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Option Exercise	21.38	5,313	113,592	5,343	Jul 16 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Sale	50.01	5,313	265,725	30	Jul 16 04:30 PM

Open in Screener

INSM

Insmed Inc

Jun 06 • 04:00PM ET

73.62

Dollar change +0.88
Percentage change 1.21	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN GILD RARE NBIX UTHR SRPT EXEL BMRN

| Held by: VTI VB IWM VXF VBK XBI IWO IBB VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-5.95	Insider Own	2.29%	Shs Outstand	181.90M	Perf Week	5.58%
Market Cap	13.41B	Forward P/E	-	EPS next Y	-3.66	Insider Trans	-17.91%	Shs Float	177.97M	Perf Month	7.82%
Income	-1013.26M	PEG	-	EPS next Q	-1.30	Inst Own	109.34%	Short Float	9.25%	Perf Quarter	-1.70%
Sales	381.03M	P/S	35.19	EPS this Y	6.01%	Inst Trans	4.41%	Short Ratio	7.23	Perf Half Y	1.64%
Book/sh	0.55	P/B	135.05	EPS next Y	30.09%	ROA	-68.42%	Short Interest	16.47M	Perf Year	29.16%
Cash/sh	6.59	P/C	11.18	EPS next 5Y	47.10%	ROE	-890.75%	52W Range	55.74 - 84.91	Perf YTD	6.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.12%	ROI	-72.45%	52W High	-13.30%	Beta	0.79
Dividend TTM	-	Quick Ratio	5.44	Sales past 5Y	21.66%	Gross Margin	75.17%	52W Low	32.08%	ATR (14)	2.54
Dividend Ex-Date	-	Current Ratio	5.86	EPS Y/Y TTM	-13.60%	Oper. Margin	-225.44%	RSI (14)	61.01	Volatility	1.39% 2.13%
Employees	1271	Debt/Eq	13.21	Sales Y/Y TTM	20.77%	Profit Margin	-265.93%	Recom	1.05	Target Price	97.00
Option/Short	Yes / Yes	LT Debt/Eq	13.10	EPS Q/Q	-34.07%	Payout	-	Rel Volume	0.68	Prev Close	72.74
Sales Surprise	1.48%	EPS Surprise	-6.07%	Sales Q/Q	22.94%	Earnings	May 08 BMO	Avg Volume	2.28M	Price	73.62
SMA20	7.18%	SMA50	5.31%	SMA200	0.74%	Trades		Volume	1,544,421	Change	1.21%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-25	Initiated	Jefferies	Buy	$105
Feb-25-25	Initiated	RBC Capital Mkts	Outperform	$100
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50
Dec-09-22	Initiated	Mizuho	Buy	$28
Dec-07-22	Initiated	Barclays	Overweight	$37
Nov-18-22	Initiated	BofA Securities	Buy	$39
Apr-27-22	Initiated	Goldman	Buy	$56
Dec-06-21	Initiated	JP Morgan	Overweight	$45
Oct-19-21	Resumed	Morgan Stanley	Overweight	$56 → $52
Oct-19-21	Resumed	Monness Crespi & Hardt	Buy	$52
Oct-08-21	Initiated	Cantor Fitzgerald	Overweight	$60
Apr-26-21	Resumed	Credit Suisse	Outperform	$60
Dec-17-20	Initiated	Berenberg	Buy	$48
Oct-12-20	Resumed	Stifel	Buy	$44
Sep-03-19	Initiated	Goldman	Buy	$30
Apr-09-19	Reiterated	H.C. Wainwright	Buy	$43 → $52

Show Previous Ratings

Jun-06-25 06:20AM	Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar? (Zacks)
06:20AM	Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar? (Zacks)
Jun-04-25 04:05PM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-29-25 06:20AM	Should Global X Russell 2000 ETF (RSSL) Be on Your Investing Radar? (Zacks)
May-28-25 07:10AM	Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference (PR Newswire)
04:05PM	Loading…
May-21-25 04:05PM	Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study (PR Newswire)
May-15-25 06:20AM	Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar? (Zacks)
May-14-25 07:39AM	Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-13-25 09:16AM	Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
10:21AM	Is Insmed Incorporated (INSM) One of the Best Cancer Stocks to Invest in for Long-Term Gain? (Insider Monkey)
May-08-25 08:15AM	Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	Insmed: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:11PM	Loading…
12:11PM	Insmed Q1 2025 Earnings Preview (Seeking Alpha)
May-06-25 06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks) -6.49%
May-04-25 11:38AM	Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy (Insider Monkey)
May-01-25 11:35AM	ClearBridge Small Cap Growth Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline (Zacks)
Apr-30-25 02:34PM	Insmed Incorporated (INSM): Among Billionaire George Soros' Mid-Cap Stocks With Huge Upside Potential (Insider Monkey)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
07:00AM	Insmed To Present at the BofA Securities 2025 Health Care Conference (PR Newswire)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 11:58AM	Insmed: Poised For Transformation Beyond ARIKAYCE (Seeking Alpha)
Apr-24-25 02:50PM	TimesSquare U.S. Mid Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 (PR Newswire)
Apr-23-25 08:46PM	Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
05:00PM	New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
02:58PM	Loading…
02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 (PR Newswire)
Apr-22-25 03:27AM	Polaris Global Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 06:20AM	Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar? (Zacks)
Apr-11-25 06:20AM	Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar? (Zacks) +5.80%
Apr-08-25 02:09PM	Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-07-25 06:20AM	Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar? (Zacks)
Apr-04-25 06:20AM	Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar? (Zacks) -5.66%
Apr-02-25 09:50AM	Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025 (Insider Monkey)
Mar-31-25 06:20AM	Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar? (Zacks)
Mar-28-25 06:20AM	Should Global X Russell 2000 ETF (RSSL) Be on Your Investing Radar? (Zacks)
Mar-25-25 05:39PM	Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
08:00AM	Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference (PR Newswire)
Mar-21-25 07:10AM	BlackRock Advantage Small Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-18-25 05:33AM	Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-10-25 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-24-25 09:15AM	International Markets and Insmed (INSM): A Deep Dive for Investors (Zacks)
08:00AM	Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis (PR Newswire)
Feb-21-25 02:04AM	Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Feb-20-25 09:30AM	Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:20AM	Insmed: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update (PR Newswire)
Feb-19-25 09:50AM	Will Insmed Incorporateds (INSM) New Drugs be Able to Peak Sales? (Insider Monkey)
Feb-17-25 09:16AM	Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
Feb-13-25 10:01AM	Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-11-25 08:00AM	Insmed To Present at March 2025 Investor Conferences (PR Newswire)
Feb-10-25 08:00AM	Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025 (PR Newswire)
Feb-07-25 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-06-25 08:00AM	FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 (PR Newswire)
Jan-24-25 03:00AM	Gene therapies have been uneven for DMD but these companies hope to turn the tide (Pharma Voice)
Jan-18-25 05:46PM	Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Jan-15-25 12:29PM	Insmeds gene therapy poised to challenge DMD landscape after IND clearance (Pharmaceutical Technology)
Jan-13-25 03:06PM	Why INSM Stock Is Advancing Today (Insider Monkey) +5.64%
Jan-10-25 08:00AM	Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 04:05PM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-02-25 08:00AM	Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-01-25 09:40AM	Why Is Insmed Incorporated (INSM) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-23-24 10:33AM	Is Insmed Incorporated (INSM) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:51AM	Should You Invest in Insmed Incorporated (INSM)? (Insider Monkey)
Dec-06-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-02-24 02:35PM	Why Is Insmed Incorporated (INSM) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
08:00AM	Insmed To Present at December 2024 Investor Conferences (PR Newswire)
Nov-07-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-06-24 08:00AM	Insmed To Present at November 2024 Investor Conferences (PR Newswire) +5.14%
Nov-04-24 09:15AM	Insmed (INSM) Reliance on International Sales: What Investors Need to Know (Zacks)
Nov-01-24 09:22AM	Do You Believe in the Growth Potential of Insmed (INSM)? (Insider Monkey)
03:03AM	Insmed Inc (INSM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:58AM	Q3 2024 Insmed Inc Earnings Call (Thomson Reuters StreetEvents)
01:12AM	Decoding Insmed Inc (INSM): A Strategic SWOT Insight (GuruFocus.com)
Oct-31-24 10:00AM	Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Insmed: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Oct-30-24 09:15AM	Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Oct-29-24 05:47PM	How to play biotech stocks: Insmed and Wave Life Sciences (Yahoo Finance Video)
Oct-24-24 04:05PM	Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List (PR Newswire)
Oct-23-24 08:00AM	Insmed Unites Across Communities Around the World During Third Annual Global Day of Good (PR Newswire)
Oct-17-24 10:01AM	Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 (PR Newswire)
Oct-09-24 05:28PM	Insmed Inc (INSM) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Oct-08-24 04:05PM	New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results (PR Newswire)
Oct-06-24 09:23AM	Insmed Inc. (INSM): Hedge Funds Are Bullish On This NASDAQ Stock Right Now (Insider Monkey)
Oct-04-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-29-24 06:38AM	Is Insmed Incorporated (INSM) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 12:25AM	Is Insmed Inc. (INSM) the Best Performing Stock in 2024? (Insider Monkey)
Sep-21-24 10:14AM	Insmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential (Insider Monkey)
Sep-11-24 05:45AM	Insmed Incorporated (INSM) Surged Following Positive Data For its Drug (Insider Monkey)
Sep-08-24 01:52AM	Insmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now (Insider Monkey)
Sep-06-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Michael Alexander	Chief Legal Officer	Jun 05 '25	Sale	73.50	1,879	138,106	67,718	Jun 06 04:53 PM
Smith Michael Alexander	Officer	Jun 05 '25	Proposed Sale	73.47	1,879	138,050		Jun 05 04:38 PM
Smith Michael Alexander	Chief Legal Officer	Jun 03 '25	Sale	71.50	1,448	103,532	69,597	Jun 04 05:38 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 03 '25	Sale	71.50	1,686	120,549	83,111	Jun 04 05:37 PM
Adsett Roger	Chief Operating Officer	Jun 03 '25	Sale	71.50	1,860	132,990	141,323	Jun 04 05:36 PM
Bonstein Sara	Chief Financial Officer	Jun 03 '25	Sale	71.50	1,579	112,898	113,288	Jun 04 05:36 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '25	Sale	71.50	1,642	117,403	118,579	Jun 04 04:42 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	71.30	3,250	231,725	100,723	Jun 04 04:41 PM
MCGIRR DAVID W J	Director	Jun 04 '25	Sale	73.27	3,000	219,810	97,723	Jun 04 04:41 PM
Lewis William	Chair and CEO	Jun 02 '25	Option Exercise	10.85	6,830	74,106	240,754	Jun 04 04:40 PM
Lewis William	Chair and CEO	Jun 02 '25	Sale	71.31	6,830	487,044	233,924	Jun 04 04:40 PM
Lewis William	Chair and CEO	Jun 03 '25	Sale	71.50	5,472	391,248	308,758	Jun 04 04:40 PM
MCGIRR DAVID W J	Director	Jun 04 '25	Proposed Sale	73.27	3,000	219,804		Jun 04 12:33 PM
Bonstein Sara	Officer	Jun 03 '25	Proposed Sale	71.50	1,579	112,898		Jun 03 05:32 PM
Flammer Martina M.D.	Officer	Jun 03 '25	Proposed Sale	71.50	1,686	120,549		Jun 03 05:24 PM
Adsett Roger	Officer	Jun 03 '25	Proposed Sale	71.50	1,860	132,990		Jun 03 05:15 PM
Smith Michael Alexander	Officer	Jun 03 '25	Proposed Sale	71.50	1,448	103,532		Jun 03 05:09 PM
Wise John Drayton	Former Officer	Jun 03 '25	Proposed Sale	71.50	1,860	132,990		Jun 03 05:00 PM
Schaeffer Orlov S Nicole	Officer	Jun 03 '25	Proposed Sale	71.50	1,642	117,403		Jun 03 04:43 PM
Lewis William	Officer	Jun 03 '25	Proposed Sale	71.50	5,472	391,248		Jun 03 04:37 PM
Smith Michael Alexander	Chief Legal Officer	May 30 '25	Sale	69.65	26,327	1,833,779	71,045	Jun 03 04:02 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Proposed Sale	71.30	3,250	231,725		Jun 03 12:50 PM
Lewis William	Officer	Jun 02 '25	Proposed Sale	71.28	6,830	486,834		Jun 02 04:35 PM
Smith Michael Alexander	Officer	May 30 '25	Proposed Sale	69.63	26,327	1,833,031		May 30 04:08 PM
Wise John Drayton	Former Officer	May 29 '25	Proposed Sale	66.60	6,691	445,620		May 29 04:22 PM
Wise John Drayton	Former Officer	May 28 '25	Proposed Sale	68.00	3,431	233,308		May 28 04:14 PM
Desjardins Clarissa	Director	May 20 '25	Buy	66.87	1,895	126,719	1,895	May 22 05:20 PM
Desjardins Clarissa	Director	May 21 '25	Buy	66.35	1,130	74,976	3,025	May 22 05:20 PM
Lewis William	Chair and CEO	May 20 '25	Option Exercise	10.85	6,830	74,106	240,754	May 22 05:18 PM
Lewis William	Chair and CEO	May 20 '25	Sale	67.65	21,057	1,424,447	314,230	May 22 05:18 PM
Lewis William	Chair and CEO	May 20 '25	Sale	67.72	6,830	462,510	233,924	May 22 05:18 PM
Wise John Drayton	Former Officer	May 20 '25	Proposed Sale	67.38	7,000	471,652		May 20 05:03 PM
Lewis William	Officer	May 20 '25	Proposed Sale	67.63	27,887	1,886,133		May 20 04:54 PM
Flammer Martina M.D.	Chief Medical Officer	May 15 '25	Sale	65.47	9,925	649,790	86,596	May 19 05:05 PM
Flammer Martina M.D.	Chief Medical Officer	May 16 '25	Sale	67.53	1,799	121,486	84,797	May 19 05:05 PM
Flammer Martina M.D.	Officer	May 15 '25	Proposed Sale	65.47	11,724	767,570		May 15 05:01 PM
Smith Michael Alexander	Chief Legal Officer	May 13 '25	Sale	67.81	4,407	298,839	92,203	May 15 04:36 PM
Smith Michael Alexander	Chief Legal Officer	May 14 '25	Sale	65.61	409	26,834	91,794	May 15 04:36 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 13 '25	Sale	67.81	4,999	338,982	115,879	May 15 04:34 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 14 '25	Sale	65.61	1,236	81,094	114,643	May 15 04:34 PM
Lewis William	Chair and CEO	May 13 '25	Sale	66.97	17,442	1,168,158	316,744	May 15 04:33 PM
Lewis William	Chair and CEO	May 14 '25	Sale	65.61	3,771	247,415	312,973	May 15 04:33 PM
Flammer Martina M.D.	Chief Medical Officer	May 13 '25	Sale	67.81	8,408	570,146	91,757	May 15 04:31 PM
Flammer Martina M.D.	Chief Medical Officer	May 14 '25	Sale	65.61	1,744	114,424	90,013	May 15 04:31 PM
Bonstein Sara	Chief Financial Officer	May 13 '25	Sale	67.81	8,870	601,475	109,993	May 15 04:29 PM
Bonstein Sara	Chief Financial Officer	May 14 '25	Sale	65.61	1,634	107,207	108,359	May 15 04:29 PM
Adsett Roger	Chief Operating Officer	May 13 '25	Sale	67.81	7,482	507,354	138,600	May 15 04:26 PM
Adsett Roger	Chief Operating Officer	May 14 '25	Sale	65.61	1,925	126,299	136,675	May 15 04:26 PM
Wise John Drayton	Former Officer	May 14 '25	Proposed Sale	65.61	401	26,309		May 14 06:23 PM
Smith Michael Alexander	Officer	May 14 '25	Proposed Sale	65.61	409	26,834		May 14 05:53 PM
Schaeffer Orlov S Nicole	Officer	May 14 '25	Proposed Sale	65.61	1,236	81,093		May 14 05:49 PM
Lewis William	Officer	May 14 '25	Proposed Sale	65.61	3,771	247,415		May 14 05:45 PM
Flammer Martina M.D.	Officer	May 14 '25	Proposed Sale	65.61	1,744	114,423		May 14 05:39 PM
Bonstein Sara	Officer	May 14 '25	Proposed Sale	65.61	1,634	107,206		May 14 05:35 PM
Adsett Roger	Officer	May 14 '25	Proposed Sale	65.61	1,925	126,299		May 14 05:30 PM
Lewis William	Officer	May 13 '25	Proposed Sale	67.81	17,442	1,182,742		May 13 05:44 PM
Bonstein Sara	Officer	May 13 '25	Proposed Sale	67.81	8,870	601,474		May 13 05:35 PM
Flammer Martina M.D.	Officer	May 13 '25	Proposed Sale	67.81	8,408	570,146		May 13 05:32 PM
Adsett Roger	Officer	May 13 '25	Proposed Sale	67.81	7,482	507,354		May 13 05:29 PM
Schaeffer Orlov S Nicole	Officer	May 13 '25	Proposed Sale	67.81	4,999	338,982		May 13 05:18 PM
Wise John Drayton	Former Officer	May 13 '25	Proposed Sale	67.81	4,610	312,604		May 13 05:12 PM
Smith Michael Alexander	Officer	May 13 '25	Proposed Sale	67.81	4,407	298,838		May 13 05:03 PM
Lewis William	Chair and CEO	May 01 '25	Option Exercise	10.85	6,830	74,106	240,754	May 02 04:43 PM
Lewis William	Chair and CEO	May 01 '25	Sale	72.57	6,830	495,668	233,924	May 02 04:43 PM
Lewis William	Officer	May 01 '25	Proposed Sale	72.54	6,830	495,448		May 01 04:33 PM
Lewis William	Chair and CEO	Apr 15 '25	Option Exercise	10.85	6,830	74,106	240,754	Apr 16 04:17 PM
Lewis William	Chair and CEO	Apr 15 '25	Sale	70.16	6,830	479,177	233,924	Apr 16 04:17 PM
Lewis William	Officer	Apr 15 '25	Proposed Sale	70.12	6,830	478,933		Apr 15 04:41 PM
Lewis William	Chair and CEO	Apr 01 '25	Option Exercise	10.85	6,830	74,106	240,754	Apr 03 04:25 PM
Lewis William	Chair and CEO	Apr 01 '25	Sale	73.58	6,830	502,577	233,924	Apr 03 04:25 PM
Lewis William	Officer	Apr 01 '25	Proposed Sale	73.55	6,830	502,352		Apr 01 04:48 PM
Lewis William	Chair and CEO	Mar 17 '25	Option Exercise	22.76	18,750	426,750	352,936	Mar 19 04:53 PM
Lewis William	Chair and CEO	Mar 17 '25	Option Exercise	10.85	6,830	74,106	240,754	Mar 19 04:53 PM
Lewis William	Chair and CEO	Mar 17 '25	Sale	77.03	18,750	1,444,241	334,186	Mar 19 04:53 PM
Lewis William	Chair and CEO	Mar 17 '25	Sale	77.04	6,830	526,179	233,924	Mar 19 04:53 PM
Lewis William	Officer	Mar 17 '25	Proposed Sale	77.00	25,580	1,969,586		Mar 17 05:03 PM
Lewis William	Chair and CEO	Mar 03 '25	Option Exercise	22.76	18,750	426,750	352,936	Mar 05 05:27 PM
Lewis William	Chair and CEO	Mar 03 '25	Option Exercise	10.85	6,830	74,106	240,754	Mar 05 05:27 PM
Lewis William	Chair and CEO	Mar 03 '25	Sale	77.79	18,750	1,458,519	334,186	Mar 05 05:27 PM
Lewis William	Chair and CEO	Mar 03 '25	Sale	77.79	6,830	531,278	233,924	Mar 05 05:27 PM
Lewis William	Officer	Mar 03 '25	Proposed Sale	77.75	25,580	1,988,965		Mar 03 05:53 PM
Lewis William	Chair and CEO	Feb 18 '25	Option Exercise	22.76	18,750	426,750	352,936	Feb 20 04:52 PM
Lewis William	Chair and CEO	Feb 18 '25	Option Exercise	10.85	6,830	74,106	240,754	Feb 20 04:52 PM
Lewis William	Chair and CEO	Feb 18 '25	Sale	81.03	18,750	1,519,279	334,186	Feb 20 04:52 PM
Lewis William	Chair and CEO	Feb 18 '25	Sale	81.03	6,830	553,442	233,924	Feb 20 04:52 PM
Bonstein Sara	Chief Financial Officer	Feb 18 '25	Sale	80.31	18,322	1,471,394	118,863	Feb 20 04:52 PM
Lewis William	Officer	Feb 18 '25	Proposed Sale	81.00	25,580	2,071,913		Feb 18 05:31 PM
Bonstein Sara	Chief Financial Officer	Feb 11 '25	Sale	80.00	13,302	1,064,160	142,204	Feb 13 05:09 PM
Bonstein Sara	Chief Financial Officer	Feb 12 '25	Sale	80.00	5,019	401,520	137,185	Feb 13 05:09 PM
Adsett Roger	Chief Operating Officer	Feb 10 '25	Sale	78.61	42,975	3,378,067	146,082	Feb 12 04:45 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 10 '25	Sale	78.61	37,828	2,973,485	100,165	Feb 12 04:45 PM
Bonstein Sara	Officer	Feb 11 '25	Proposed Sale	80.00	36,643	2,931,440		Feb 11 04:42 PM
Flammer Martina M.D.	Officer	Feb 10 '25	Proposed Sale	78.57	37,828	2,972,328		Feb 10 04:52 PM
Adsett Roger	Officer	Feb 10 '25	Proposed Sale	78.57	42,975	3,376,752		Feb 10 04:45 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 06 '25	Sale	80.90	33,055	2,674,150	138,053	Feb 07 05:11 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 07 '25	Sale	79.59	60	4,775	137,993	Feb 07 05:11 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Feb 06 '25	Sale	80.90	23,500	1,901,150	120,878	Feb 07 05:11 PM
Adsett Roger	Chief Operating Officer	Feb 06 '25	Sale	80.90	45,605	3,689,445	189,157	Feb 07 05:11 PM
Adsett Roger	Chief Operating Officer	Feb 07 '25	Sale	79.57	100	7,957	189,057	Feb 07 05:11 PM
Lewis William	Chair and CEO	Feb 06 '25	Sale	80.90	79,350	6,419,415	453,894	Feb 07 05:11 PM

RYTM

Rhythm Pharmaceuticals Inc

INSM

Insmed Inc

Upgrade your FINVIZ experience